基于网络药理学探讨舒心口服液治疗冠心病心绞痛的作用机制  

Mechanism of Shuxin Oral Liquid in the treating angina pectoris of coronary heart disease based on network pharmacology

作　　者：王发文 况春燕[2] 吴金鉴 舒馨仪 杨春 WANG Fa-wen;KUANG Chun-yan;WU Jin-jian(Guizhou University of Traditional Chinese Medicine,Guiyang 550000,China;Guizhou Provincial People’s Hospital,Guiyang 550000,China;不详)

机构地区：[1]贵州中医药大学,贵阳550000 [2]贵州省人民医院,贵阳550000

出　　处：《中国处方药》2024年第5期21-26,共6页Journal of China Prescription Drug

基　　金：国家自然科学基金项目(81560056);贵州省第十二批优秀青年科技人才项目(黔科合平台人才[2019]5662);贵州省科技计划项目(黔科合基础[2018]1097);贵州省留学人员科技活动择优资助项目(黔人项目资助合同[2018]0003号);贵州省科技平台及人才团队计划项目(黔科合平台人才2017-5405)。

摘　　要：目的基于网络药理学探讨舒心口服液治疗冠心病心绞痛的作用机制。方法通过TCMSP、化源网、Pubchem、SwissTarget-Prediction等平台获取舒心口服液活性成分及对应靶点,借助GeneCards数据库获取冠心病心绞痛相关靶点,对药物靶点和疾病靶点取交集,获取交集靶点。使用Cytoscape软件,构建“药物-成分-靶点”网络图,利用STRING平台获取交集蛋白相互作用信息的TSV文件,使用Cytoscape绘制蛋白质相互作用(PPI)网络,MCODE插件进行蛋白聚类分析,利用DAVID数据库与微生信进行基因本体论功能富集分析(GO)和京都基因与基因组百科全书富集分析(KEGG)及绘图。结果筛选出舒心口服液55个活性成分,包括基质分解素-1(Stromelysin-1)、转录因子p65(Transcription factor p65)、M-乙酰胆碱受体M3(Muscarinic acetylcholine receptor M3);作用于冠心病心绞痛的潜在作用靶点有160个,包括JUN、AKT1、TP53、RELA、MAPK1、TNF等;KEGG分析得到167条相关通路,主要调节肿瘤坏死因子(TNF)信号通路、磷脂酰肌醇-蛋白激酶B(PI3K-Akt)信号通路、白细胞介素-17(IL-17)信号通路、松弛素信号通路等发挥治疗冠心病心绞痛的作用。结论舒心口服液治疗冠心病心绞痛具有多靶点、多通路的特点,为舒心口服液治疗冠心病心绞痛的生物机制研究提供数据支撑,同时为进一步实验研究提供参考。Objective To explore the mechanism of Shuxin Oral Liquid in treating angina pectoris of coronary heart disease based on network pharmacology.Methods The active components and corresponding targets of Shuxin Oral Liquid were obtained by TCMSP,Huayuan network,Pubchem,SwissTargetPrediction and so forth.The coronary heart disease and angina pectoris related targets were obtained by GeneCards database,and the intersection targets were obtained by intersection of drug targets and disease targets.The network diagram of"drug-ingredient-target"was constructed by Cytoscape software,the TSV file of intersection protein interaction information was obtained by STRING platform,PPI network was drawn by Cytoscape,protein cluster analysis was carried out by MCODE plug-in,GO and KEGG analysis and mapping were carried out by using DAVID database and Weishengxin.Results 55 active components of Shuxin Oral Liquid were screened,including stromelysin-1,Transcription factor p65 and M-acetylcholine receptor M3.There are 160 potential targets for angina pectoris,including JUN,AKT1,TP53,RELA,MAPK1,TNF and so on.KEGG analysis showed 167 related pathways,mainly regulating TNF signal pathway,PI3K-Akt signal pathway,IL-17 signal pathway and relaxin signal pathway to play a role in the treatment of angina pectoris of coronary heart disease.Conclusion Shuxin Oral Liquid has the characteristics of multi-target and multi-pathway in the treating angina pectoris of coronary heart disease,which provides data support for the study of the biological mechanism of Shuxin Oral Liquid in the treatment of angina pectoris of coronary heart disease,and provides reference for further experimental research.

关 键 词：舒心口服液 冠心病心绞痛 网络药理学 

分 类 号：R285[医药卫生—中药学]